JPRN-jRCT2080224176
Completed
Phase 1
A Phase 1 Study to Evaluate Safety and Tolerability of NKTR-214 (BMS-986321) Administered in Combination with Nivolumab (BMS-936558) in Advanced Malignant Tumors
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Bristol-Myers Squibb K.K.
- Enrollment
- 6
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologic or cytological confirmation of an advanced (metastatic and/or unresectable) malignant solid tumor with measurable disease per RECIST v1\.1\.
- •Life expectancy \>12 weeks.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\.
Exclusion Criteria
- •Active, known or suspected autoimmune disease.
- •History of organ transplant that requires use of immune suppressive agents.
- •Prior surgery or radiotherapy within 14 days of Cycle 1 Day 1\. Participants must have recovered from all radiation\-related, toxicities and not requiring
- •corticosteroids.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study of REGN1979 (anti-CD20 and anti- CD3) and REGN2810 in Patients with a Specific Type of Blood CancerEUCTR2015-001697-17-DERegeneron Pharmaceuticals, Inc172
Active, not recruiting
Phase 1
Study of REGN1979 (anti-CD20 and anti- CD3) and REGN2810 (anti-PD-1) in Patients with a Specific Type of Blood CancerB-cell malignanciesMedDRA version: 18.1Level: PTClassification code 10003903Term: B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10003917Term: B-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10026945Term: Mature B-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10067184Term: Burkitt's leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10020267Term: Hodgkin's disease refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10003890Term: B precursor type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10020266Term: Hodgkin's disease recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001697-17-ESRegeneron Pharmaceuticals, Inc318
Not yet recruiting
Phase 1
Study to evaluate safety of LNP8701 in patients with different types of Metastatic solid cancersHealth Condition 1: D499- Neoplasm of unspecified behavior of unspecified siteCTRI/2024/08/072373upin Limited
Completed
Phase 1
Testing safety of a live bacterial therapy for the treatment of Chronic ConstipatioFunctional Constipation (FC)Irritable Bowel Syndrome - Constipation (IBS-C)Idiopathic Constipation (IC)Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12620001077954Servatus Ltd38
Completed
Phase 1
A Phase I Study of SCC244 in Japanese Patients with Advanced Solid TumorsSolid tumorsJPRN-jRCT2080225124Shanghai Haihe Pharmaceutical Co., Ltd.6